SEARCH

SEARCH BY CITATION

References

  • 1
    Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables in canine mitral regurgitation attributable to myxomatous valve disease in dogs. J Vet Intern Med 2008;22:120128.
  • 2
    Buchanan J. Prevalence of cardiovascular disorders. In: Fox P, Sisson D, Moise N, eds. Canine and Feline Cardiology, 2nd ed. Philadelphia, PA: WB Saunders; 1999:457470.
  • 3
    Häggström J, Pedersen H, Kvart C. New insights into degenerative mitral valve disease in dogs. Vet Clin North Am Small Anim Pract 2004;34:12091226.
  • 4
    Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc 1998;213:15731577.
  • 5
    Häggström J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST study. J Vet Intern Med 2008;22:11241135.
  • 6
    Oyama MA, Rush JE, O'Sullivan ML, et al. Perceptions and priorities of owners of dogs with heart disease regarding quality versus quantity of life for their pets. J Am Vet Med Assoc 2008;233:104108.
  • 7
    The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:718.
  • 8
    The COVE Study Grup. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the coperative veterinary enalapril study group. J Vet Intern Med 1995;9:243252.
  • 9
    Lombard C, Jöns O, Bussadori C. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249261.
  • 10
    Smith P, French A, Van Israël N, et al. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005;46:121130.
  • 11
    Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009;23:11421150.
  • 12
    Hansson K, Häggström J, Kvart C, et al. Left atrial to aortic root root indices using two-dimensional and M-mode echocardiography in dogs with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568757.
  • 13
    Cornell C, Kittleson M, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311321.
  • 14
    Buchanan J, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194199.
  • 15
    Kienle RD, Thomas WP. Veterinary diagnostic ultrasound. In: Nyland TG, Mattoon JS, eds. Echocardiography. Philadelphia, PA: W.B. Saunders; 1995:198255.
  • 16
    Kvart C, Haggstrom J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:8088.
  • 17
    Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ 1990;300:230235.
  • 18
    Dunderdale K, Thompson DR, Miles JN, et al. Quality-of-life measurement in chronic heart failure: Do we take account of the patient perspective? Eur J Heart Fail 2005;7:572582.
  • 19
    Leidy NK, Rentz AM, Zyczynski TM. Evaluating health-related quality-of-life outcomes in patients with congestive heart failure. A review of recent randomised controlled trials. Pharm Econ 1999;15:1946.
  • 20
    Stanek EJ, Oates MB, McGhan WF, et al. Preferences for treatment outcomes in patients with heart failure: Symptoms versus survival. J Card Fail 2000;6:225232.
  • 21
    Jepson RE, Elliott J, Brodbelt D, et al. Effect of control of systolic blood pressure on survival in cats with systemic hypertension. J Vet Intern Med 2007;21:402409.
  • 22
    Lane P. Handling drop-out in longitudinal clinical trials: A comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93106.
  • 23
    Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:176182.
  • 24
    Cleland JG. How to assess new treatments for the management of heart failure: Composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 2002;4:243247.
  • 25
    Cleland JG, Charlesworth A, Lubsen J, et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the “patient journey”) in patients with heart failure: A report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol 2006;47:16031611.
  • 26
    O'Grady MR, Minors SL, O'Sullivan ML, et al. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med 2008;22:897904.
  • 27
    Nallamothu BK, Payvar S, Wang Y, et al. Admission body temperature and mortality in elderly patients hospitalized for heart failure. J Am Coll Cardiol 2006;47:25632564.
  • 28
    Ahmed A, Aboshady I, Munir SM, et al. Decreasing body temperature predicts early rehospitalization in congestive heart failure. J Card Fail 2008;14:489496.
  • 29
    Wolley R, Smith P, Munro E, et al. Effect of treatment type on vertebral heart size in dogs with myxomatous mitral valve disease. Intern J Appl Res Vet Med 2007;5:4348.
  • 30
    Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: Implications for management. Circulation 2008;118:22982303.
  • 31
    Summerfield NJ, Boswood A, O'Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). J Vet Intern Med 2012;26:13371349.
  • 32
    De Luca L, Klein L, Udelson JE, et al. Hyponatremia in patients with heart failure. Am J Cardiol 2005;96:19L23L.
  • 33
    Horwich TB, Kalantar-Zadeh K, MacLellan RW, et al. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008;155:883889.
  • 34
    Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:17801786.
  • 35
    Adrogue HJ, Madias NE. Hyponatremia. New Eng J Med 2000;342:15811589.
  • 36
    Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 2005;95:14B23B.
  • 37
    Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) trial. Acute Card Care 2007;9:8286.
  • 38
    Freeman LM, Rush JE, Farabaugh AE, et al. Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease. J Am Vet Med Assoc 2005;226:18641868.